retatrutide nejm 2023 obesity trial ly3437943 This week's most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist for — A Phase 2 https://t.co/jNL1GNnHPT #Endocrinology Eli Lilly infiltrates anti-obesity market

Overall, as metabolic impairments and mitochondrial dysfunction are key drivers of AD pathology, exercise-mediated hepatokine regulation offers a viable strategy for preventing or slowing AD progression

Cannabis smoking can also produce rapid changes to heart rate, dizziness, and blood pressure

Clinical data shows sustained weight loss when patients remain on medication, with many continuing treatment beyond initial weight loss phases

These medications potently and selectively inhibit the enzymatic activity of DPP-4, enhancing the effectiveness of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), which are the primary incretins (endogenous glucoregulatory peptides, [39,40,41])

Other prescriptions: One pill (Contrave) combines naltrexone and bupropion to blunt cravings and hunger

Intestinal mucosal microbial activity was found to be decreased in mice with diarrhea induced by a high-fat and high-protein diet (Zhou et al., 2023)